Lymphoma Research Foundation awards over $5.7M in grants

Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma

Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.

December 13, 2024

Vol.50 No.46

In Brief

Krish Patel joins Sarah Cannon as director of lymphoma research

Krish Patel was appointed director of lymphoma research at Sarah Cannon Research Institute.

November 22, 2024

Vol.50 No.44

Clinical Trials & Tribulations

How we improved the treatment of Hodgkin lymphoma

Hodgkin lymphoma has long been a model disease in the field of oncology—one of the first diseases we learned to cure with radiation and ultimately chemotherapy.

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo

A new first-line treatment involving the PD-1 inhibitor nivolumab for advanced-stage classic Hodgkin lymphoma could soon make its way into clinics.

October 18, 2024

Vol.50 No.39

By McKenzie Prillaman

In Brief

Qure.ai completes $65M Series D funding round

Qure.ai has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the U.S. market and other countries, increase investment in foundational AI models, and enable complementary med-tech company acquisitions.

October 04, 2024

Vol.50 No.37

Guest Editorial

Group chairs propose funding strategy to jump-start correlative studies

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”

September 20, 2024

Vol.50 No.35

By Peter J. O'Dwyer

Lymphoma Research Foundation awards over $5.7M in grants

YOU MAY BE INTERESTED IN

Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma

Krish Patel joins Sarah Cannon as director of lymphoma research

How we improved the treatment of Hodgkin lymphoma

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo

Qure.ai completes $65M Series D funding round

Group chairs propose funding strategy to jump-start correlative studies

Renew today!

Subscriber content

Never miss an issue!

Login

Lymphoma Research Foundation awards over $5.7M in grants

YOU MAY BE INTERESTED IN

Antibody shows encouraging results for treating high-risk follicular lymphoma and marginal zone lymphoma

Krish Patel joins Sarah Cannon as director of lymphoma research

How we improved the treatment of Hodgkin lymphoma

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?Phase III trial finds improved PFS, side effects with nivolumab+chemo

Qure.ai completes $65M Series D funding round

Group chairs propose funding strategy to jump-start correlative studies

Never miss an issue!

Login

Is nivolumab superior to standard of care for classic Hodgkin lymphoma?
Phase III trial finds improved PFS, side effects with nivolumab+chemo